NASDAQ · ZVRA
Healthcare · Biotechnology
$10.73
Up+$0.03 (+0.28%)
Updated Oct 7, 2026, 2:23 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZVRA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ZVRA closed at $10.73 after 21 trading sessions, down 15.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $10.76 | $10.875 | $10.445 | $10.73 | 614.59K |
| Oct 5, 2026 | $10.01 | $10.805 | $10.00 | $10.70 | 1.98M |
| Oct 2, 2026 | $10.24 | $10.24 | $9.845 | $9.99 | 951.87K |
| Oct 1, 2026 | $10.91 | $10.965 | $10.15 | $10.18 | 1.3M |
| Sep 30, 2026 | $11.37 | $11.38 | $10.935 | $10.97 | 1.82M |
| Sep 29, 2026 | $11.28 | $11.50 | $11.20 | $11.34 | 1.35M |
| Sep 28, 2026 | $11.01 | $11.365 | $10.892 | $11.30 | 751.31K |
| Sep 25, 2026 | $11.29 | $11.30 | $11.01 | $11.04 | 678.56K |
| Sep 24, 2026 | $11.28 | $11.315 | $11.06 | $11.26 | 593.99K |
| Sep 23, 2026 | $11.58 | $11.58 | $11.15 | $11.32 | 735.89K |
| Sep 22, 2026 | $11.85 | $11.8787 | $11.5101 | $11.58 | 601.2K |
| Sep 21, 2026 | $11.72 | $11.88 | $11.521 | $11.67 | 714.95K |
| Sep 18, 2026 | $11.76 | $11.93 | $11.52 | $11.61 | 1.48M |
| Sep 17, 2026 | $11.96 | $12.29 | $11.79 | $11.84 | 1.59M |
| Sep 16, 2026 | $11.65 | $11.835 | $11.61 | $11.80 | 795.11K |
| Sep 15, 2026 | $12.335 | $12.335 | $11.52 | $11.65 | 916.55K |
| Sep 14, 2026 | $12.03 | $12.18 | $11.96 | $12.05 | 621.97K |
| Sep 11, 2026 | $12.23 | $12.30 | $11.96 | $12.01 | 583.01K |
| Sep 10, 2026 | $11.99 | $12.23 | $11.88 | $12.06 | 675.5K |
| Sep 9, 2026 | $12.79 | $12.79 | $12.02 | $12.04 | 923.59K |
| Sep 8, 2026 | $12.24 | $12.90 | $12.18 | $12.675 | 1.14M |
The latest Smart Investors Daily articles mentioning ZVRA.
Company
Market Activity
Research & News
ZVRA research
Company profile and research snapshot.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 6, 2026 | Citizens | Market Outperform | — |
| Jul 27, 2026 | Guggenheim | Buy | — |
| Jul 27, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Zevra Therapeutics, Inc. (ZVRA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDTCompany ParticipantsNeil McFarlane -...
Yahoo · Sep 2, 2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the following investor conferences in New York, NY. Cantor Global Healthcare Conference Fireside chat on Wednesday, September 9, 2026, at 9:10 a.m. ET Morgan Stanley 24th Annual Global Healthcare C
Benzinga · Sep 2, 2026
US stock futures lower, MongoDB shares down 13.4% in pre-market trading after earnings beat estimates. Other stocks also declining in pre-market.
Benzinga · Aug 25, 2026
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZVRA.
